Sparks commentary - Herantis Pharma

Healthcare

Sparks - Herantis Pharma

More on this equity
Herantis (HEL: HRTIS) presents positive Phase Ib update
Published by Arron Aatkar, PhD

Herantis Pharma has announced an encouraging update from its ongoing Phase Ib trial for lead asset HER-096, which is being developed as a potential disease-modifying treatment for Parkinson’s disease (PD). Analysis of the part 1 of the Phase 1b trial provided new pharmacokinetic data for HER-096, confirming the expected dosing interval of 2 or 3 subcutaneous doses per week. Further, part 2 of the study has commenced, including the first dosing of a participant diagnosed with PD. Top-line data are anticipated in Q325.

 

 

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.